653 related articles for article (PubMed ID: 17303121)
1. Effects of angiotensin-converting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy.
Zheng Z; Chen H; Xu X; Li C; Gu Q
Exp Eye Res; 2007 Apr; 84(4):745-52. PubMed ID: 17303121
[TBL] [Abstract][Full Text] [Related]
2. Beta-adrenergic receptor regulation of pigment epithelial-derived factor expression in rat retina.
Lashbrook BL; Steinle JJ
Auton Neurosci; 2005 Aug; 121(1-2):33-9. PubMed ID: 15961351
[TBL] [Abstract][Full Text] [Related]
3. Variable oxygen and retinal VEGF levels: correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopathy.
Werdich XQ; McCollum GW; Rajaratnam VS; Penn JS
Exp Eye Res; 2004 Nov; 79(5):623-30. PubMed ID: 15500821
[TBL] [Abstract][Full Text] [Related]
4. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats.
Kusari J; Zhou S; Padillo E; Clarke KG; Gil DW
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5152-9. PubMed ID: 17962468
[TBL] [Abstract][Full Text] [Related]
5. Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina.
Masuzawa K; Jesmin S; Maeda S; Zaedi S; Shimojo N; Miyauchi T; Goto K
Exp Biol Med (Maywood); 2006 Jun; 231(6):1090-4. PubMed ID: 16741055
[TBL] [Abstract][Full Text] [Related]
6. Diabetic retinopathy: VEGF, bFGF and retinal vascular pathology.
Song E; Dong Y; Han LN; Sui DM; Xu Q; Wang XR; Wu JX
Chin Med J (Engl); 2004 Feb; 117(2):247-51. PubMed ID: 14975211
[TBL] [Abstract][Full Text] [Related]
7. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade.
Ristori C; Filippi L; Dal Monte M; Martini D; Cammalleri M; Fortunato P; la Marca G; Fiorini P; Bagnoli P
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):155-70. PubMed ID: 20739470
[TBL] [Abstract][Full Text] [Related]
8. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Nagai N; Izumi-Nagai K; Oike Y; Koto T; Satofuka S; Ozawa Y; Yamashiro K; Inoue M; Tsubota K; Umezawa K; Ishida S
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4342-50. PubMed ID: 17724226
[TBL] [Abstract][Full Text] [Related]
9. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey.
Witmer AN; Blaauwgeers HG; Weich HA; Alitalo K; Vrensen GF; Schlingemann RO
Invest Ophthalmol Vis Sci; 2002 Mar; 43(3):849-57. PubMed ID: 11867607
[TBL] [Abstract][Full Text] [Related]
10. [Effects of vascular endothelial growth factor and basic fibroblast growth factor in early stage diabetic retinopathy and their molecular pathological mechanism].
Song E; Dong Y; Sui DM; Zhao XZ; Wu JX
Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(11):996-9. PubMed ID: 12899804
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes.
Gilbert RE; Kelly DJ; Cox AJ; Wilkinson-Berka JL; Rumble JR; Osicka T; Panagiotopoulos S; Lee V; Hendrich EC; Jerums G; Cooper ME
Diabetologia; 2000 Nov; 43(11):1360-7. PubMed ID: 11126403
[TBL] [Abstract][Full Text] [Related]
12. Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo.
Hattori T; Matsubara A; Taniguchi K; Ogura Y
Curr Eye Res; 2010 Feb; 35(2):146-54. PubMed ID: 20136425
[TBL] [Abstract][Full Text] [Related]
13. VEGF-initiated blood-retinal barrier breakdown in early diabetes.
Qaum T; Xu Q; Joussen AM; Clemens MW; Qin W; Miyamoto K; Hassessian H; Wiegand SJ; Rudge J; Yancopoulos GD; Adamis AP
Invest Ophthalmol Vis Sci; 2001 Sep; 42(10):2408-13. PubMed ID: 11527957
[TBL] [Abstract][Full Text] [Related]
14. Altered expression of genes related to blood-retina barrier disruption in streptozotocin-induced diabetes.
Klaassen I; Hughes JM; Vogels IM; Schalkwijk CG; Van Noorden CJ; Schlingemann RO
Exp Eye Res; 2009 Jun; 89(1):4-15. PubMed ID: 19284967
[TBL] [Abstract][Full Text] [Related]
15. Captopril inhibits capillary degeneration in the early stages of diabetic retinopathy.
Zhang JZ; Xi X; Gao L; Kern TS
Curr Eye Res; 2007 Oct; 32(10):883-9. PubMed ID: 17963108
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of vitreoretinal VEGF elevation and blood-retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine.
Kusari J; Zhou SX; Padillo E; Clarke KG; Gil DW
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1044-51. PubMed ID: 19710406
[TBL] [Abstract][Full Text] [Related]
17. Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy.
Yang LP; Sun HL; Wu LM; Guo XJ; Dou HL; Tso MO; Zhao L; Li SM
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2319-27. PubMed ID: 19011009
[TBL] [Abstract][Full Text] [Related]
18. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.
Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H
Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666
[TBL] [Abstract][Full Text] [Related]
19. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice.
Ebrahimian TG; Tamarat R; Clergue M; Duriez M; Levy BI; Silvestre JS
Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):65-70. PubMed ID: 15528473
[TBL] [Abstract][Full Text] [Related]
20. Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma.
Arafat HA; Gong Q; Chipitsyna G; Rizvi A; Saa CT; Yeo CJ
J Am Coll Surg; 2007 May; 204(5):996-1005; discussion 1005-6. PubMed ID: 17481528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
